In July, the new column of Cancer Drug Resistance (CDR) - "Special Collection" was officially launched.
On June 28, as announced by Clarivate Analytics in the Journal Citation Reports (JCR), Journal of the Cancer Drug Resistance (CDR) has achieved its first Impact Factor of 3.7.
In June, the 2022 Scopus CiteScore of CDR was officially released, which is 5.5.
In June, CDR was officially changed from quarterly publication to continuous publication.
In August, CDR is accepted for inclusion in Emerging Sources Citation Index (ESCI).
In May, CDR is officially indexed in PubMed Central® (PMC).
In March, CDR was indexed in Scopus.
In December, the estimated impact factor was 2.461. The total citations of papers published in 2018 and 2019 were 224 times, and the total number of reviews and original articles published were 91. Click the link for details of the CDR citation: https://oaepublishstorage.blob.core.windows.net/cdruploadedfiles/Citations_of_CDR_as_of_Dec_31_2020.xls.
In August, the work of expanding the Editorial Board of CDR came to a successful conclusion. A total of 30 scientists with significant international influence in the field of cancer drug resistance joined the Editor Board, with the ambition to help create a better future for CDR.
In March, CDR became a member of the Committee on Publication Ethics (COPE).
In March, CDR was founded with Professor Godefridus J. Peters as the Editor-in-Chief. The inaugural issue was officially released online on March 19, 2018.